Detail of the clinical trial

Title of the trial A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer (CheckMate 77T, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 77T)
EudraCT number 2019-000262-38
Protocol number CA209-77T
Sponsor Bristol-Myers Squibb International Corporation, Chaussée de la Hulpe 185, 1170 Brussels, Belgium
Indications Oncology
Diagnosis Lung Cancer
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2019
Date of approval by Institute (SÚKL) 8.8.
Date of approval by EC 18.7.2019
Date of initiation CT in ČR 26.11.2019
Date of ending CT in ČR
Sites Thomayerova nemocnice, Pneumologická klinika 1. LF a TN,Vídeňská 800,Praha 4,140 59
Všeobecná fakultní nemocnice v Praze, Onkologická klinika VFN a 1. LF UK,U Nemocnice 2,Praha 2,128 08

‹‹ Back to list